This company listing is no longer active
A890 Stock Overview
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Adocia SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.28 |
| 52 Week High | €4.30 |
| 52 Week Low | €2.76 |
| Beta | 1.07 |
| 1 Month Change | -7.87% |
| 3 Month Change | 3.14% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -0.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| A890 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.6% | -1.2% | 1.7% |
| 1Y | n/a | -23.0% | 2.3% |
Return vs Industry: Insufficient data to determine how A890 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how A890 performed against the German Market.
Price Volatility
| A890 volatility | |
|---|---|
| A890 Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: A890's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine A890's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 110 | Gérard Soula | www.adocia.com |
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company’s clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide.
Adocia SA Fundamentals Summary
| A890 fundamental statistics | |
|---|---|
| Market cap | €29.58m |
| Earnings (TTM) | -€7.90m |
| Revenue (TTM) | €13.95m |
2.1x
P/S Ratio-3.7x
P/E RatioIs A890 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A890 income statement (TTM) | |
|---|---|
| Revenue | €13.95m |
| Cost of Revenue | €27.62m |
| Gross Profit | -€13.68m |
| Other Expenses | -€5.78m |
| Earnings | -€7.90m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Mar 15, 2023
| Earnings per share (EPS) | -0.89 |
| Gross Margin | -98.08% |
| Net Profit Margin | -56.64% |
| Debt/Equity Ratio | -560.6% |
How did A890 perform over the long term?
See historical performance and comparison